Florence Tantot

437 total citations
26 papers, 123 citations indexed

About

Florence Tantot is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Florence Tantot has authored 26 papers receiving a total of 123 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Florence Tantot's work include Renal cell carcinoma treatment (19 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Florence Tantot is often cited by papers focused on Renal cell carcinoma treatment (19 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Florence Tantot collaborates with scholars based in France, Belgium and United States. Florence Tantot's co-authors include Laurence Albigès, Bernard Escudier, Cécile Dalban, Brigitte Laguerre, Gwénaëlle Gravis, Sylvie Négrier, Christine Chevreau, Frédéric Rolland, Antoine Thiery-Vuillemin and Marine Gross‐Goupil and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Frontiers in Oncology.

In The Last Decade

Florence Tantot

23 papers receiving 122 citations

Peers

Florence Tantot
Comparison fields: 5 of 25
  • Pulmonary and Respiratory Medicine 85
  • Oncology 83
  • Molecular Biology 28
  • Surgery 21
  • Cancer Research 16
Replace Ornella Cantale with:
Ornella Cantale Italy
Sherif Raouf United Kingdom
Urbano Anido Herranz Spain
Jasnoor Malhotra United States
Pierre-Emmanuel Brachet France
Karim Amrane France
Aiping Zhou China
Cixin He United States
David Queiroz Borges Muniz Brazil
Aurelia Alexandru Romania
Ornella Cantale Italy View profile →
Citations per field, relative to Florence Tantot
Florence Tantot · 1×
Citations per year, relative to Florence Tantot
Florence Tantot · 1×

Countries citing papers authored by Florence Tantot

Since Specialization
Citations

This map shows the geographic impact of Florence Tantot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florence Tantot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florence Tantot more than expected).

Fields of papers citing papers by Florence Tantot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florence Tantot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florence Tantot. The network helps show where Florence Tantot may publish in the future.

Co-authorship network of co-authors of Florence Tantot

This figure shows the co-authorship network connecting the top 25 collaborators of Florence Tantot. A scholar is included among the top collaborators of Florence Tantot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florence Tantot. Florence Tantot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
2023 ·Immuno-Oncology Technology ·(unknown), Marie Naigeon, Ronan Flippot, Cécile Dalban, Aude Desnoyer, Nathalie Rioux‐Leclercq, Catherine Sautès‐Fridman, Maxime Meylan, Yann Vano, Benoit Beuselinck, Salem Chouaı̈b, (unknown), Florence Tantot, (unknown), (unknown), Laurence Albigès
1
2
Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.
2023 ·Journal of Clinical Oncology ·Lucía Carril-Ajuria, Marie Naigeon, Cécile Dalban, Aude Desnoyer, (unknown), Catherine Sautès‐Fridman, Maxime Meylan, Yann Vano, (unknown), Salem Chouaı̈b, (unknown), Florence Tantot, Ronan Flippot, Bernard Escudier, Laurence Albigès, Nathalie Chaput
1
3
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
2023 ·European Urology Oncology ·(unknown), Cécile Dalban, Stéphane Oudard, Christine Chevreau, Brigitte Laguerre, Philippe Barthélémy, Delphine Borchiellini, Lionnel Geoffrois, Sylvie Négrier, Florence Joly, Antoine Thiery-Vuillemin, Marine Gross‐Goupil, Frédéric Rolland, Frank Priou, Hakim Mahammedi, Florence Tantot, Bernard Escudier, Sylvie Chabaud, Laurence Albigès, Gwénaëlle Gravis
1
4
Serum soluble MAdCAM-1: A new biomarker for cancer immunotherapy.
2023 ·Journal of Clinical Oncology ·Carolina Alves Costa Silva, Marine Fidelle, (unknown), Cécile Dalban, Silvia Zoppi, Anna Reni, Conrad Rauber, Imran Lahmar, (unknown), (unknown), Catherine Sautès‐Fridman, Maxime Meylan, Yann Vano, (unknown), Salem Chouaı̈b, Florence Tantot, Bernard Escudier, Laurence Zitvogel, Lisa Derosa, Laurence Albigès
2
5
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
2022 ·Clinical Genitourinary Cancer ·Elie Rassy, Cécile Dalban, Émeline Colomba, Lisa Derosa, Carolina Alves Costa Silva, Sylvie Négrier, Christine Chevreau, Gwénaëlle Gravis, Stéphane Oudard, Brigitte Laguerre, Philippe Barthélémy, M. Gross Goupil, Lionnel Geoffrois, Frédéric Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, Laurence Albigès
13
6
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group
2022 ·Critical Reviews in Oncology/Hematology ·Ariane Lapierre, Christophe Hennequin, (unknown), (unknown), (unknown), Marie‐Claude Biston, G. Créhange, R. de Crevoisier, Jean‐Luc Dumas, (unknown), A. Lisbona, Dominique Pasquier, S. Mathoulin Pelissier, P. Graff-Cailleaud, P. Pommier, Paul Sargos, Antoine Simon, S. Supiot, Florence Tantot, O. Chapet
10
7
Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study.
2022 ·Journal of Clinical Oncology ·(unknown), Cécile Dalban, Christine Chevreau, Gwénaëlle Gravis, Sylvie Négrier, Brigitte Laguerre, Marine Gross‐Goupil, Sylvain Ladoire, (unknown), Lionnel Geoffrois, (unknown), Frank Priou, (unknown), (unknown), Philippe Barthélémy, Florence Tantot, Bernard Escudier, Sylvie Chabaud, Laurence Albigès, Constance Thibault
2
8
The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study.
2022 ·Journal of Clinical Oncology ·(unknown), Marie Naigeon, Cécile Dalban, Aude Desnoyer, (unknown), Catherine Sautès‐Fridman, Maxime Meylan, Yann Vano, (unknown), Salem Chouaı̈b, (unknown), Florence Tantot, Bernard Escudier, Laurence Albigès, Nathalie Chaput
0
9
Baseline circulating soluble factors as predictors of response to nivolumab in metastatic clear cell renal cell carcinoma (mRCC): A validation study within the NIVOREN GETUG-AFU 26 translational study.
2022 ·Journal of Clinical Oncology ·Lucía Carril-Ajuria, Marie Naigeon, Cécile Dalban, Aude Desnoyer, Nathalie Rioux‐Leclercq, Catherine Sautès‐Fridman, Maxime Meylan, Yann Vano, (unknown), Salem Chouaı̈b, (unknown), Florence Tantot, Ronan Flippot, Bernard Escudier, Laurence Albigès, Nathalie Chaput
2
10
689P Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
2021 ·Annals of Oncology ·Lisa Kinget, Eduard Roussel, Diether Lambrechts, Bram Boeckx, Annelies Verbiest, Jessica Zucman‐Rossi, Gabrielle Couchy, Cécile Dalban, Maxime Meylan, Sylvie Chabaud, Yann Vano, Catherine Sautès‐Fridman, Wolf H. Fridman, Marcella Baldewijns, Maarten Albersen, N. Costedoat‐Chalumeau, Florence Tantot, Nathalie Chaput, Benoit Beuselinck, Laurence Albigès
2
11
697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
2021 ·Annals of Oncology ·(unknown), Lisa Derosa, Cécile Dalban, Émeline Colomba, Sylvie Négrier, Christine Chevreau, Gwénaëlle Gravis, Stéphane Oudard, Brigitte Laguerre, Philippe Barthélémy, Delphine Borchiellini, Marine Gross‐Goupil, Lionnel Geoffrois, Frédéric Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, Laurence Albigès
5
12
687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
2021 ·Annals of Oncology ·(unknown), Marie Naigeon, Cécile Dalban, Aude Desnoyer, Nathalie Rioux‐Leclercq, Catherine Sautès‐Fridman, Maxime Meylan, (unknown), Benoit Beuselinck, Salem Chouaı̈b, (unknown), Florence Tantot, Bernard Escudier, Laurence Albigès, Nathalie Chaput
0
13
Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial.
2021 ·Journal of Clinical Oncology ·Émeline Colomba, Ronan Flippot, Cécile Dalban, Sylvie Négrier, Christine Chevreau, Gwénaëlle Gravis, Stéphane Oudard, Brigitte Laguerre, Philippe Barthélémy, M. Gross Goupil, Lionnel Geoffrois, Frédéric Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, Laurence Albigès
2
14
646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer
2021 ·Annals of Oncology ·Pierre Blanchard, (unknown), Xavier Artignan, Joan Carles, Philippe Ronchin, (unknown), Salvador Villà Freixa, R. Valdagni, Paul Sargos, (unknown), (unknown), Aline Guillot, I. Latorzeff, Enrique Gallardo, M.I. Sáez, Sophie Abadie‐Lacourtoisie, Mostefa Bennamoun, Ali Hasbini, Florence Tantot, Karim Fizazi
0
15
712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial
2020 ·Annals of Oncology ·(unknown), Cécile Dalban, Brigitte Laguerre, Sylvain Ladoire, Philippe Barthélémy, Stéphane Oudard, Florence Joly, Gwénaëlle Gravis, Christine Chevreau, L. Geoffrois, Élise Deluche, Frédéric Rolland, Delphine Topart, Stéphane Culine, Sylvie Négrier, Hakim Mahammedi, Florence Tantot, Bernard Escudier, Ronan Flippot, Laurence Albigès
1
16
700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
2020 ·Annals of Oncology ·Maxime Meylan, Benoit Beuselinck, Cécile Dalban, Yann Vano, Nathalie Leclercq, Catherine Sautès‐Fridman, Eduard Roussel, Annelies Verbiest, Nathalie Chaput, Stéphane Terry, Christine Chevreau, Marine Gross‐Goupil, Aude Fléchon, Brigitte Laguerre, Sylvie Chabaud, Florence Tantot, Diether Lambrechts, Bernard Escudier, Wolf H. Fridman, Laurence Albigès
7
17
Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
2019 ·Frontiers in Oncology ·(unknown), Jochen Walz, Serge Brunelle, Jeanne Thomassin‐Piana, Naji Salem, Mathilde Guérin, Cécile Vicier, (unknown), Laurence Albigès, Florence Tantot, Soazig Nénan, G. Pignot, Gwénaëlle Gravis
16
18
Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome
2019 ·Annals of Oncology ·Aude Desnoyer, (unknown), Damien Drubay, Émilie Lanoy, Yann Vano, N. Costedoat‐Chalumeau, Salem Chouaı̈b, Benoit Beuselinck, Florence Tantot, Bernard Escudier, Nathalie Chaput, Laurence Albigès
4
19
NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)
2019 ·Annals of Oncology ·Yann Vano, N. Costedoat‐Chalumeau, Cécile Dalban, Catherine Sautès‐Fridman, Antoine Bougoüin, Nathalie Chaput, Salem Chouaı̈b, Benoit Beuselinck, Christine Chevreau, Marine Gross‐Goupil, Sylvie Négrier, Brigitte Laguerre, Delphine Borchiellini, (unknown), Wolf H. Fridman, Sylvie Chabaud, Florence Tantot, Janice Monteiro, Bernard Escudier, Laurence Albigès
5
20
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.
2019 ·Journal of Clinical Oncology ·Laurence Albigès, Sylvie Négrier, Cécile Dalban, Christine Chevreau, Gwénaëlle Gravis, Stéphane Oudard, Brigitte Laguerre, Philippe Barthélémy, Delphine Borchiellini, Marine Gross‐Goupil, Lionnel Geoffrois, Frédéric Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, (unknown)
21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ornella Cantale Breakdown of academic impact, for papers by Sherif Raouf Breakdown of academic impact, for papers by Urbano Anido Herranz Breakdown of academic impact, for papers by Jasnoor Malhotra Breakdown of academic impact, for papers by Pierre-Emmanuel Brachet Breakdown of academic impact, for papers by Karim Amrane Breakdown of academic impact, for papers by Aiping Zhou Breakdown of academic impact, for papers by Cixin He Breakdown of academic impact, for papers by David Queiroz Borges Muniz Breakdown of academic impact, for papers by Aurelia Alexandru
Rankless by CCL
2026